AstraZeneca Pharma News and Updates

Keep track of all breaking news on AstraZeneca Pharma from all sources in a single place.

07 Apr 2026

8695.50

2.14%

AstraZenecainks MoU with TelanganaforAI-enabled lung cancer screening

Business Line

AstraZeneca will facilitate the deployment ofQure.ai's AI-powered chest X-ray solution, to be integrated into routine workflows at public health facilities across Telangana

AstraZeneca Pharma India Ltd. is trading above its 100 day SMA of 8524.7

AstraZeneca Pharma India Ltd.

10 Feb 2026

8695.50

2.14%

AstraZeneca gets Indian regulator's nod to market cancer drug Imfinzi

Business Standard

AstraZeneca Pharma India Ltd on Tuesday said it has received permission from India's drug regulator to market Durvalumab solution for infusion used in cancer treatment for an additional indication. The company has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, to import for sale and distribution of Durvalumab solution for infusion of strengths 120 mg/2.4 ml and 500 mg/10 ml (brand name Imfinzi) for an additional indication, AstraZeneca Pharma said in a regulatory filing. Through this approval, Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab as monotherapy in endometrial cancer which is mismatch repair deficient (dMMR). The receipt of this permission paves way for the marketing of Durvalumab solution for infusion 1

AstraZeneca Pharma India Ltd. is trading below its 150 day SMA of 8744.8

AstraZeneca Pharma India Ltd.

04 Feb 2026

8695.50

2.14%

AstraZeneca gets CDSCO approval for Durvalumab in gastric cancer treatment

Business Line

Gastric cancer remains a major health challenge in India, ranking as the seventh most common cancer with over 64,000 new cases diagnosed annually

AstraZeneca Pharma India Ltd.'s price crossed above 100Day SMA today

Walmart becomes first retailer to hit $1 trillion market valuation

Business Line | 03 Feb 2026

AstraZeneca Pharma India Ltd.

10 Jan 2026

8695.50

2.14%

Walmart to join Nasdaq 100 from January 20 as AstraZeneca exits the index

livemint

Walmart Inc. will join the Nasdaq 100 Index on January 20, as AstraZeneca exits. This follows Walmart's last year stock transfer from the NYSE to Nasdaq. Details here.

AstraZeneca Pharma India Ltd. is trading below its 150 day SMA of 8744.8

Walmart to replace AstraZeneca on Nasdaq-100 Index on January 20

livemint | 10 Jan 2026 3 more

AstraZeneca Pharma India Ltd.

18 Nov 2025, 01:49PM

8695.50

2.14%

AstraZeneca, Sun Pharma sign deal to distribute hyperkalaemia drug in India

Business Standard

AstraZeneca Pharma India and Sun Pharmaceutical Industries have formed an exclusive brand partnership to promote and distribute SZC for hyperkalaemia treatment under separate brands

AstraZeneca Pharma India Ltd.'s price crossed above 100Day SMA today

AstraZeneca and Sun Pharma to co-market key hyperkalaemia drug in India

Business Line | 17 Nov 2025, 07:54PM

AstraZeneca Pharma India Ltd.

19 Oct 2025, 12:09PM

8695.50

2.14%

AstraZeneca's Datroway extends survival in aggressive breast cancer

Business Line

Patients with triple-negative breast cancer who were given the drug, Datroway, had a median overall survival of 23.7 months, compared with 18.7 months for those given just chemotherapy

AstraZeneca Pharma India Ltd. is trading below its 150 day SMA of 8744.8

AstraZeneca Pharma India Ltd.

11 Oct 2025

8695.50

2.14%

Trump announces AstraZeneca drug price cuts for tariff reprieve

Business Line

The deal will see AstraZeneca slash what it charges for its medicines in exchange for three years of relief from threatened tariffs on the pharmaceutical industry

AstraZeneca Pharma India Ltd.'s price crossed above 100Day SMA today

AstraZeneca to strike landmark drug price deal with Trump administration

Business Standard | 10 Oct 2025

AstraZeneca Pharma India Ltd.

07 Oct 2025

8695.50

2.14%

AstraZeneca gets regulator's nod to market cancer drug in India

Business Line

With this approval, Trastuzumab Deruxtecan is now indicated for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumours

AstraZeneca Pharma India Ltd. is trading below its 150 day SMA of 8744.8

AstraZeneca receives CDSCO's approval to market cancer drug in India

Business Standard | 07 Oct 2025

AstraZeneca Pharma India Ltd.

06 Oct 2025

8695.50

2.14%

AstraZeneca Signs $555 Million Deal To Develop AI-Led Gene-Editing Therapy

NDTV Profit

The technology was developed by Jennifer Doudna, for which she won the Nobel Prize for Chemistry in 2020.

AstraZeneca Pharma India Ltd. is trading below its 150 day SMA of 8744.8

AstraZeneca Pharma India Ltd.

07 Sep 2025

8695.50

2.14%

AstraZeneca's lung cancer combination boosted survival in key study

Business Standard

The combination helped patients with a specific type of advanced non-small cell lung cancer live for 47.5 months at the median, the longest survival benefit ever reported

AstraZeneca Pharma India Ltd. is trading above its 100 day SMA of 8524.7

Is AstraZeneca Pharma India Ltd. worth buying?

151 Votes:

Buy 71.52%

Sell 19.21%

Hold 9.27%